Paxman Q2’23 - Strong growth and Positive Outlook
2023-08-25 09:33:00
Redeye sees continued strong sales progression driven by the right underlying factors. The better-than-expected sales and continued bright outlook confirm our positive stance on the potential for Paxman in the future. With some minor adjustments to our estimates due to the beat of our estimates and a slight increase in cost, we maintain our fair value range and range of SEK 39 to SEK 130 per share with a Base case value of SEK 86 per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/